Search results
Results from the WOW.Com Content Network
Management of ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) focuses on symptoms management, as no treatments that address the root cause of the illness are available. [1]: 29 Pacing, or regulating one's activities to avoid triggering worse symptoms, is the most common management strategy for post-exertional malaise.
Risk factors for statin induced rhabdomyolysis include older age, renal impairment, high dose statins and use of medications that reduce the breakdown of statins (such as CYP3A4 inhibitors) or fibrates. [68] Persistent liver enzyme abnormalities (usually elevated in hepatic transaminases) have been documented. [69]
Part of the power of statins lies in the fact that they cause few side effects. “Generally, about 90 out of 100 people have no trouble with a stain,” says Dr. Blumenthal.
The term “fatigue” trivialises the illness and discourages research into potential treatments. [91] According to a survey of medical trainees at a school in the United States, a condition described as "chronic fatigue syndrome" is considered less serious than a condition described as "myalgic encephalopathy". [92] [93]
The term post-infectious fatigue syndrome was initially proposed as a subset of "chronic fatigue syndrome" with a documented triggering infection, but might also be used as a synonym of ME/CFS or as a broader set of fatigue conditions after infection. [26] Many individuals with ME/CFS object to the term chronic fatigue syndrome. They consider ...
It is the hallmark symptom of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and common in long COVID and fibromyalgia. [3] [1] PEM is often severe enough to be disabling, and is triggered by ordinary activities that healthy people tolerate. Typically, it begins 12–48 hours after the activity that triggers it, and lasts for days ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug.In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [1]
In 2001, the ME Association decided to use the term Myalgic Encephalopathy rather than Myalgic Encephalomyelitis, stating that they felt this was a more appropriate description and was a name that doctors "cannot simply dismiss on the grounds that it is pathologically inaccurate in relation to ME (or research defined cases of CFS)".